These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16088719)

  • 1. The antibiotic treatment of severe community-acquired pneumonia admitted to the critical care unit.
    Cunha BA
    Semin Respir Crit Care Med; 2000; 21(1):61-9. PubMed ID: 16088719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe community-acquired pneumonia: an Australian perspective.
    Wilson PA; Ferguson J
    Intern Med J; 2005 Dec; 35(12):699-705. PubMed ID: 16313544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival.
    Bodí M; Rodríguez A; Solé-Violán J; Gilavert MC; Garnacho J; Blanquer J; Jimenez J; de la Torre MV; Sirvent JM; Almirall J; Doblas A; Badía JR; García F; Mendia A; Jordá R; Bobillo F; Vallés J; Broch MJ; Carrasco N; Herranz MA; Rello J;
    Clin Infect Dis; 2005 Dec; 41(12):1709-16. PubMed ID: 16288392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Q fever community-acquired pneumonia in a patient with Crohn's disease on immunosuppressive therapy.
    Nausheen S; Cunha BA
    Heart Lung; 2007; 36(4):300-3. PubMed ID: 17628200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Q fever community-acquired pneumonia (CAP) mimicking Legionnaires' disease: Clinical significance of cold agglutinins, anti-smooth muscle antibodies and thrombocytosis.
    Cunha BA; Nausheen S; Busch L
    Heart Lung; 2009; 38(4):354-62. PubMed ID: 19577708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
    Cantón R; Lode H; Graninger W; Milkovich G
    Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimizing the antibiotics policy in The Netherlands. VIII. Revised SWAB guidelines for antimicrobial therapy in adults with community-acquired pneumonia].
    Schouten JA; Prins JM; Bonten M; Degener JE; Janknegt R; Hollander JM; Jonkers R; Wijnands W; Verheij T; Sachs A; Kullberg BJ
    Ned Tijdschr Geneeskd; 2005 Nov; 149(45):2495-500. PubMed ID: 16304886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
    Niven DJ; Laupland KB
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):69-81. PubMed ID: 19622058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.
    Micek ST; Kollef KE; Reichley RM; Roubinian N; Kollef MH
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3568-73. PubMed ID: 17682100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
    File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
    Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing community-acquired pneumonia: a European perspective.
    Lode HM
    Respir Med; 2007 Sep; 101(9):1864-73. PubMed ID: 17548187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy.
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2005 Dec; 26(6):575-616. PubMed ID: 16388429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of aetiological tests for guiding antibiotic therapy in community-acquired pneumonia.
    Strålin K
    Int J Antimicrob Agents; 2008 Jan; 31(1):3-11. PubMed ID: 17920819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of new therapies for severe community-acquired pneumonia.
    Restrepo MI; Anzueto A
    Curr Opin Infect Dis; 2006 Dec; 19(6):557-64. PubMed ID: 17075331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etiology of community-acquired pneumonia in immunocompetent adults].
    Moreno B R; Riquelme O R
    Rev Chilena Infectol; 2005; 22 Suppl 1():s18-25. PubMed ID: 16163415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials.
    Mandell LA
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S189-92. PubMed ID: 18986288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.